Cardiome tipping Merck $20M to settle tiff; Boehringer's Pradaxa bleeds hundreds of lawsuits;

@FiercePharma: AbbVie shares fall in first day of 'when-issued' trading. Story | Follow @FiercePharma

> Cardiome Pharma ($CRME) will pony up $20 million to Merck & Co. ($MRK) to settle issues over a heart drug they were partnering on. Story 

> Boehringer Ingelheim is now defending itself against hundreds of lawsuits tied to bleeding episodes, some fatal, in patients taking its blood thinner Pradaxa. Story

> Canadian company QLT has its last product for sale--an experimental treatment for a disease that can cause blindness--and it's valuing the product at $750 million. Item

> Indian officials expect the prices of 650 commonly used drugs to fall by up to 15% now that the government has set price controls. Story  

> Executives with two supermarkets in Lexington, KY, that cater to Hispanics admitted to smuggling drugs in from Mexico and selling them at their stores. Release

Medical Device News

 @FierceMedDev: Exact Sciences heads to the FDA with cancer diagnostic. Story | Follow @FierceMedDev

@MarkHFierce: MIT's Robert Langer is at it again--using porcupine quills as a model for next-generation medical device needles. More | Follow @MarkHFierce

 @DamianFierce: The effort to delay the medical device tax has picked up some Democratic support. Report | Follow @DamianFierce

> Japan's regulators approve Thoratec's HeartMate II pump. News

> India lures med tech manufacturing interest. Story

> Covidien's blood monitor will ship with GE's infant warmers. Item

Biotech News

 @FierceBiotech: GSK employs mobile phones to up vaccination rates in Africa. Story | Follow @FierceBiotech

@JohnCFierce: Sofinnova reaps $312M for its dedicated life sciences fund. Wished we saw more of these. News | Follow @JohnCFierce

> Teva chief Levin inks $376M deal on Xenon pain program. Article

> Isis grabs $31M in quick AstraZeneca cash during busy dealmaking round. Report

> Exclusive: Cerulean hauls in $13M, revs up deal talks as it nears PhIIb cancer data. News

Biotech Research News

> New molecule opens door to lymphoma combination therapy. News

> Seattle Genetics' next-gen antibody-drug conjugate tackles leukemia in the lab. Report

> Preclinical data snags GlaxoSmithKline's attention in $335M cancer immunotherapy deal. Article

> MicroRNAs could heal broken hearts. Item

Pharma Manufacturing News

> Novo selling Bangladeshi-made insulin after plant fires up. Story

> Congress investigating compounding pharmacy trade group. Item

> Endo reports oversized problem with oversized pain meds. Article

> Pharma files lawsuit against California drug-disposal law. News

And Finally... The consumer health side of GlaxoSmithKline ($GSK) has set up a smoking-cessation website to market products such as patches, lozenges and nicotine-laced gum. Item


 

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.